Reata brain cancer therapy shows strong activity
14th Nov 2006, 06:12 GMT
Reata Pharmaceuticals has reported interim results from its ongoing phase I trial of RTA 744 in advanced primary brain tumors that showed evidence of strong drug activity.
Reata brain cancer therapy shows strong activity related news:
- Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential — Medscape Headlines
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- U-M researchers use nanoparticles to target brain cancer — EurekAlert! - Cancer
- Anti-cancer drug shows early promise in pulmonary hypertension — EurekAlert! - Breaking News
- Long-Term Data Shows No Increase In Cancer Cases From Biologic Therapy — Health News from Medical News Today
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit — EurekAlert! - Medicine and Health
- Other highlights in the November 15 JNCI — EurekAlert! - Biology
- WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions — Cardiology News from StratCenter.com
- Scientists Design A PSA-Activated Protoxin That Kills Prostate Cancer — Health News from Medical News Today
- Targeted cancer drugs may work by disrupting balance of cellular signals — EurekAlert! - Cancer
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol
- ZymoGenetics, Serono present positive results for atacicept